(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium
Drug discovery for malaria has been transformed in the last 5 years by the discovery of many new lead compounds identified by phenotypic screening. The process of developing these compounds as drug leads and studying the cellular responses they induce is revealing new targets that regulate key proce...
Saved in:
| Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 111; no. 50; pp. E5455 - E5462 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
National Academy of Sciences
16.12.2014
National Acad Sciences |
| Series | PNAS Plus |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Drug discovery for malaria has been transformed in the last 5 years by the discovery of many new lead compounds identified by phenotypic screening. The process of developing these compounds as drug leads and studying the cellular responses they induce is revealing new targets that regulate key processes in the Plasmodium parasites that cause malaria. We disclose herein that the clinical candidate (+)-SJ733 acts upon one of these targets, ATP4. ATP4 is thought to be a cation-transporting ATPase responsible for maintaining low intracellular Na ⁺ levels in the parasite. Treatment of parasitized erythrocytes with (+)-SJ733 in vitro caused a rapid perturbation of Na ⁺ homeostasis in the parasite. This perturbation was followed by profound physical changes in the infected cells, including increased membrane rigidity and externalization of phosphatidylserine, consistent with eryptosis (erythrocyte suicide) or senescence. These changes are proposed to underpin the rapid (+)-SJ733-induced clearance of parasites seen in vivo. Plasmodium falciparum ATPase 4 ( pfatp4 ) mutations that confer resistance to (+)-SJ733 carry a high fitness cost. The speed with which (+)-SJ733 kills parasites and the high fitness cost associated with resistance-conferring mutations appear to slow and suppress the selection of highly drug-resistant mutants in vivo. Together, our data suggest that inhibitors of PfATP4 have highly attractive features for fast-acting antimalarials to be used in the global eradication campaign.
Significance Useful antimalarial drugs must be rapidly acting, highly efficacious, and have low potential for developing resistance. (+)-SJ733 targets a Plasmodium cation-transporting ATPase, ATP4. (+)-SJ733 cleared parasites in vivo as quickly as artesunate by specifically inducing eryptosis/senescence in infected, treated erythrocytes. Although in vitro selection of pfatp4 mutants with (+)-SJ733 proceeded with moderate frequency, during in vivo selection of pbatp4 mutants, resistance emerged slowly and produced marginally resistant mutants with poor fitness. In addition, (+)-SJ733 met all other criteria for a clinical candidate, including high oral bioavailability, a high safety margin, and transmission blocking activity. These results demonstrate that targeting ATP4 has great potential to deliver useful drugs for malaria eradication. |
|---|---|
| AbstractList | Drug discovery for malaria has been transformed in the last 5 years by the discovery of many new lead compounds identified by phenotypic screening. The process of developing these compounds as drug leads and studying the cellular responses they induce is revealing new targets that regulate key processes in the Plasmodium parasites that cause malaria. We disclose herein that the clinical candidate (+)-SJ733 acts upon one of these targets, ATP4. ATP4 is thought to be a cation-transporting ATPase responsible for maintaining low intracellular Na ⁺ levels in the parasite. Treatment of parasitized erythrocytes with (+)-SJ733 in vitro caused a rapid perturbation of Na ⁺ homeostasis in the parasite. This perturbation was followed by profound physical changes in the infected cells, including increased membrane rigidity and externalization of phosphatidylserine, consistent with eryptosis (erythrocyte suicide) or senescence. These changes are proposed to underpin the rapid (+)-SJ733-induced clearance of parasites seen in vivo. Plasmodium falciparum ATPase 4 ( pfatp4 ) mutations that confer resistance to (+)-SJ733 carry a high fitness cost. The speed with which (+)-SJ733 kills parasites and the high fitness cost associated with resistance-conferring mutations appear to slow and suppress the selection of highly drug-resistant mutants in vivo. Together, our data suggest that inhibitors of PfATP4 have highly attractive features for fast-acting antimalarials to be used in the global eradication campaign.
Significance Useful antimalarial drugs must be rapidly acting, highly efficacious, and have low potential for developing resistance. (+)-SJ733 targets a Plasmodium cation-transporting ATPase, ATP4. (+)-SJ733 cleared parasites in vivo as quickly as artesunate by specifically inducing eryptosis/senescence in infected, treated erythrocytes. Although in vitro selection of pfatp4 mutants with (+)-SJ733 proceeded with moderate frequency, during in vivo selection of pbatp4 mutants, resistance emerged slowly and produced marginally resistant mutants with poor fitness. In addition, (+)-SJ733 met all other criteria for a clinical candidate, including high oral bioavailability, a high safety margin, and transmission blocking activity. These results demonstrate that targeting ATP4 has great potential to deliver useful drugs for malaria eradication. Drug discovery for malaria has been transformed in the last 5 years by the discovery of many new lead compounds identified by phenotypic screening. The process of developing these compounds as drug leads and studying the cellular responses they induce is revealing new targets that regulate key processes in the Plasmodium parasites that cause malaria. We disclose herein that the clinical candidate (+)-SJ733 acts upon one of these targets, ATP4. ATP4 is thought to be a cation-transporting ATPase responsible for maintaining low intracellular Na(+) levels in the parasite. Treatment of parasitized erythrocytes with (+)-SJ733 in vitro caused a rapid perturbation of Na(+) homeostasis in the parasite. This perturbation was followed by profound physical changes in the infected cells, including increased membrane rigidity and externalization of phosphatidylserine, consistent with eryptosis (erythrocyte suicide) or senescence. These changes are proposed to underpin the rapid (+)-SJ733-induced clearance of parasites seen in vivo. Plasmodium falciparum ATPase 4 (pfatp4) mutations that confer resistance to (+)-SJ733 carry a high fitness cost. The speed with which (+)-SJ733 kills parasites and the high fitness cost associated with resistance-conferring mutations appear to slow and suppress the selection of highly drug-resistant mutants in vivo. Together, our data suggest that inhibitors of PfATP4 have highly attractive features for fast-acting antimalarials to be used in the global eradication campaign. Significance Useful antimalarial drugs must be rapidly acting, highly efficacious, and have low potential for developing resistance. (+)-SJ733 targets a Plasmodium cation-transporting ATPase, ATP4. (+)-SJ733 cleared parasites in vivo as quickly as artesunate by specifically inducing eryptosis/senescence in infected, treated erythrocytes. Although in vitro selection of pfatp4 mutants with (+)-SJ733 proceeded with moderate frequency, during in vivo selection of pbatp4 mutants, resistance emerged slowly and produced marginally resistant mutants with poor fitness. In addition, (+)-SJ733 met all other criteria for a clinical candidate, including high oral bioavailability, a high safety margin, and transmission blocking activity. These results demonstrate that targeting ATP4 has great potential to deliver useful drugs for malaria eradication. Drug discovery for malaria has been transformed in the last 5 years by the discovery of many new lead compounds identified by phenotypic screening. The process of developing these compounds as drug leads and studying the cellular responses they induce is revealing new targets that regulate key processes in the Plasmodium parasites that cause malaria. We disclose herein that the clinical candidate (+)-SJ733 acts upon one of these targets, ATP4. ATP4 is thought to be a cation-transporting ATPase responsible for maintaining low intracellular Na + levels in the parasite. Treatment of parasitized erythrocytes with (+)-SJ733 in vitro caused a rapid perturbation of Na + homeostasis in the parasite. This perturbation was followed by profound physical changes in the infected cells, including increased membrane rigidity and externalization of phosphatidylserine, consistent with eryptosis (erythrocyte suicide) or senescence. These changes are proposed to underpin the rapid (+)-SJ733-induced clearance of parasites seen in vivo. Plasmodium falciparum ATPase 4 ( pfatp4 ) mutations that confer resistance to (+)-SJ733 carry a high fitness cost. The speed with which (+)-SJ733 kills parasites and the high fitness cost associated with resistance-conferring mutations appear to slow and suppress the selection of highly drug-resistant mutants in vivo. Together, our data suggest that inhibitors of PfATP4 have highly attractive features for fast-acting antimalarials to be used in the global eradication campaign. Useful antimalarial drugs must be rapidly acting, highly efficacious, and have low potential for developing resistance. (+)-SJ733 targets a Plasmodium cation-transporting ATPase, ATP4. (+)-SJ733 cleared parasites in vivo as quickly as artesunate by specifically inducing eryptosis/senescence in infected, treated erythrocytes. Although in vitro selection of pfatp4 mutants with (+)-SJ733 proceeded with moderate frequency, during in vivo selection of pbatp4 mutants, resistance emerged slowly and produced marginally resistant mutants with poor fitness. In addition, (+)-SJ733 met all other criteria for a clinical candidate, including high oral bioavailability, a high safety margin, and transmission blocking activity. These results demonstrate that targeting ATP4 has great potential to deliver useful drugs for malaria eradication. Drug discovery for malaria has been transformed in the last 5 years by the discovery of many new lead compounds identified by phenotypic screening. The process of developing these compounds as drug leads and studying the cellular responses they induce is revealing new targets that regulate key processes in the Plasmodium parasites that cause malaria. We disclose herein that the clinical candidate (+)-SJ733 acts upon one of these targets, ATP4. ATP4 is thought to be a cation-transporting ATPase responsible for maintaining low intracellular Na + levels in the parasite. Treatment of parasitized erythrocytes with (+)-SJ733 in vitro caused a rapid perturbation of Na + homeostasis in the parasite. This perturbation was followed by profound physical changes in the infected cells, including increased membrane rigidity and externalization of phosphatidylserine, consistent with eryptosis (erythrocyte suicide) or senescence. These changes are proposed to underpin the rapid (+)-SJ733-induced clearance of parasites seen in vivo. Plasmodium falciparum ATPase 4 ( pfatp4 ) mutations that confer resistance to (+)-SJ733 carry a high fitness cost. The speed with which (+)-SJ733 kills parasites and the high fitness cost associated with resistance-conferring mutations appear to slow and suppress the selection of highly drug-resistant mutants in vivo. Together, our data suggest that inhibitors of PfATP4 have highly attractive features for fast-acting antimalarials to be used in the global eradication campaign. |
| Author | Aaron N. Endsley Jonathon Diep Gloria Holbrook Dennis E. Kyle Marie-Eve Myrand-Lapierre Adele M. Lehane Ane Rodríguez-Alejandre Spencer Knapp Yandira Salinas Adelaide S. M. Dennis Jian Liu Laura Sanz Kiaran Kirk Fangyi Zhu María G. Gómez Anupam Pradhan María Santos Martínez Iñigo Angulo-Barturen David A. Fidock Anang Shelat Julie A. Clark Marcus C. S. Lee Xiaoyan Deng Jon C. Mirsalis David M. Floyd Angela K. Carrillo David M. Shackleford Sandra Duffy Francisco-Javier Gamo María Belén Jiménez-Díaz W. Armand Guiguemde Greg Fedewa R. Kiplin Guy Charles C. Kim Vicky M. Avery Philip D. Stein Gregory Miller Mariana Justino de Almeida Zheng Wang Kathleen G. O’Loughlin Jeremy Horst Martina Sigal Joseph L. DeRisi Hongshen Ma Daniel Ebert David Waterson Susan A. Charman Natalie J. Spillman Amy Matheny Santiago Ferrer |
| Author_xml | – sequence: 1 givenname: María Belén surname: Jiménez-Díaz fullname: Jiménez-Díaz, María Belén organization: Tres Cantos Medicines Development Campus-Diseases of the Developing World, GlaxoSmithKline, Tres Cantos 28760, Madrid, Spain – sequence: 2 givenname: Daniel surname: Ebert fullname: Ebert, Daniel organization: Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158-2330 – sequence: 3 givenname: Yandira surname: Salinas fullname: Salinas, Yandira organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105 – sequence: 4 givenname: Anupam surname: Pradhan fullname: Pradhan, Anupam organization: Department of Global Health, College of Public Health, University of South Florida, Tampa, FL 33612 – sequence: 5 givenname: Adele M surname: Lehane fullname: Lehane, Adele M organization: Research School of Biology, Australian National University, Canberra, ACT, Australia 2601 – sequence: 6 givenname: Marie-Eve surname: Myrand-Lapierre fullname: Myrand-Lapierre, Marie-Eve organization: Departments of Mechanical Engineering and Urologic Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z4 – sequence: 7 givenname: Kathleen G surname: O'Loughlin fullname: O'Loughlin, Kathleen G organization: Toxicology and Pharmacokinetics, SRI International, Menlo Park, CA 94025 – sequence: 8 givenname: David M surname: Shackleford fullname: Shackleford, David M organization: Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia 3052 – sequence: 9 givenname: Mariana surname: Justino de Almeida fullname: Justino de Almeida, Mariana organization: Department of Microbiology and Immunology and Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY 10032 – sequence: 10 givenname: Angela K surname: Carrillo fullname: Carrillo, Angela K organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105 – sequence: 11 givenname: Julie A surname: Clark fullname: Clark, Julie A organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105 – sequence: 12 givenname: Adelaide S M surname: Dennis fullname: Dennis, Adelaide S M organization: Research School of Biology, Australian National University, Canberra, ACT, Australia 2601 – sequence: 13 givenname: Jonathon surname: Diep fullname: Diep, Jonathon organization: Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158-2330 – sequence: 14 givenname: Xiaoyan surname: Deng fullname: Deng, Xiaoyan organization: Departments of Mechanical Engineering and Urologic Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z4 – sequence: 15 givenname: Sandra surname: Duffy fullname: Duffy, Sandra organization: Eskitis Institute, Brisbane Innovation Park, Nathan Campus, Griffith University, QLD, Australia 4111 – sequence: 16 givenname: Aaron N surname: Endsley fullname: Endsley, Aaron N organization: Toxicology and Pharmacokinetics, SRI International, Menlo Park, CA 94025 – sequence: 17 givenname: Greg surname: Fedewa fullname: Fedewa, Greg organization: Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158-2330 – sequence: 18 givenname: W Armand surname: Guiguemde fullname: Guiguemde, W Armand organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105 – sequence: 19 givenname: María G surname: Gómez fullname: Gómez, María G organization: Tres Cantos Medicines Development Campus-Diseases of the Developing World, GlaxoSmithKline, Tres Cantos 28760, Madrid, Spain – sequence: 20 givenname: Gloria surname: Holbrook fullname: Holbrook, Gloria organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105 – sequence: 21 givenname: Jeremy surname: Horst fullname: Horst, Jeremy organization: Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158-2330 – sequence: 22 givenname: Charles C surname: Kim fullname: Kim, Charles C organization: Division of Experimental Medicine, University of California, San Francisco, CA 94110 – sequence: 23 givenname: Jian surname: Liu fullname: Liu, Jian organization: Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854; and – sequence: 24 givenname: Marcus C S surname: Lee fullname: Lee, Marcus C S organization: Department of Microbiology and Immunology and Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY 10032 – sequence: 25 givenname: Amy surname: Matheny fullname: Matheny, Amy organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105 – sequence: 26 givenname: María Santos surname: Martínez fullname: Martínez, María Santos organization: Tres Cantos Medicines Development Campus-Diseases of the Developing World, GlaxoSmithKline, Tres Cantos 28760, Madrid, Spain – sequence: 27 givenname: Gregory surname: Miller fullname: Miller, Gregory organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105 – sequence: 28 givenname: Ane surname: Rodríguez-Alejandre fullname: Rodríguez-Alejandre, Ane organization: Tres Cantos Medicines Development Campus-Diseases of the Developing World, GlaxoSmithKline, Tres Cantos 28760, Madrid, Spain – sequence: 29 givenname: Laura surname: Sanz fullname: Sanz, Laura organization: Tres Cantos Medicines Development Campus-Diseases of the Developing World, GlaxoSmithKline, Tres Cantos 28760, Madrid, Spain – sequence: 30 givenname: Martina surname: Sigal fullname: Sigal, Martina organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105 – sequence: 31 givenname: Natalie J surname: Spillman fullname: Spillman, Natalie J organization: Research School of Biology, Australian National University, Canberra, ACT, Australia 2601 – sequence: 32 givenname: Philip D surname: Stein fullname: Stein, Philip D organization: Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854; and – sequence: 33 givenname: Zheng surname: Wang fullname: Wang, Zheng organization: Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854; and – sequence: 34 givenname: Fangyi surname: Zhu fullname: Zhu, Fangyi organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105 – sequence: 35 givenname: David surname: Waterson fullname: Waterson, David organization: Medicines for Malaria Venture, International Center Cointrin, 1215 Geneva, Switzerland – sequence: 36 givenname: Spencer surname: Knapp fullname: Knapp, Spencer organization: Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854; and – sequence: 37 givenname: Anang surname: Shelat fullname: Shelat, Anang organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105 – sequence: 38 givenname: Vicky M surname: Avery fullname: Avery, Vicky M organization: Eskitis Institute, Brisbane Innovation Park, Nathan Campus, Griffith University, QLD, Australia 4111 – sequence: 39 givenname: David A surname: Fidock fullname: Fidock, David A organization: Department of Microbiology and Immunology and Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY 10032 – sequence: 40 givenname: Francisco-Javier surname: Gamo fullname: Gamo, Francisco-Javier organization: Tres Cantos Medicines Development Campus-Diseases of the Developing World, GlaxoSmithKline, Tres Cantos 28760, Madrid, Spain – sequence: 41 givenname: Susan A surname: Charman fullname: Charman, Susan A organization: Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia 3052 – sequence: 42 givenname: Jon C surname: Mirsalis fullname: Mirsalis, Jon C organization: Toxicology and Pharmacokinetics, SRI International, Menlo Park, CA 94025 – sequence: 43 givenname: Hongshen surname: Ma fullname: Ma, Hongshen organization: Departments of Mechanical Engineering and Urologic Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z4 – sequence: 44 givenname: Santiago surname: Ferrer fullname: Ferrer, Santiago organization: Tres Cantos Medicines Development Campus-Diseases of the Developing World, GlaxoSmithKline, Tres Cantos 28760, Madrid, Spain – sequence: 45 givenname: Kiaran surname: Kirk fullname: Kirk, Kiaran organization: Research School of Biology, Australian National University, Canberra, ACT, Australia 2601 – sequence: 46 givenname: Iñigo surname: Angulo-Barturen fullname: Angulo-Barturen, Iñigo organization: Tres Cantos Medicines Development Campus-Diseases of the Developing World, GlaxoSmithKline, Tres Cantos 28760, Madrid, Spain – sequence: 47 givenname: Dennis E surname: Kyle fullname: Kyle, Dennis E organization: Department of Global Health, College of Public Health, University of South Florida, Tampa, FL 33612 – sequence: 48 givenname: Joseph L surname: DeRisi fullname: DeRisi, Joseph L organization: Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158-2330 – sequence: 49 givenname: David M surname: Floyd fullname: Floyd, David M organization: Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854; and – sequence: 50 givenname: R Kiplin surname: Guy fullname: Guy, R Kiplin email: kip.guy@stjude.org organization: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105; kip.guy@stjude.org |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25453091$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkstLHTEUxkOx1Kvturs20I2ljuY1j2wEEdtahArqOpxJMvdGZpLbZEb0v2-Ge3v7WDWbBM7v-_jOyTlAez54i9BbSk4oqfnp2kM6oYIKxmg-L9CCEkmLSkiyhxaEsLpoBBP76CClB0KILBvyCu2zUpQ8gwv0dPTpY3H7reb8GAPWvfNOQ481eOMMjBZ3IeIBeogO8LiCEYMeU37FMC1X-PzuRuAxYOfNpC2OsHYGr0Iai8Eal_Ume1qI4HM1dPimhzQE46bhNXrZQZ_sm-19iO4_X95dfC2uv3-5uji_LnRJ-FiwtrM1A00bxizlRjJoWS2FlqJjHTOUtFzUvKWt7LgRjTamalrdZjHophT8EJ1tfNdTmzNp68cIvVpHN0B8VgGc-rvi3Uotw6MSLA-lYtngaGsQw4_JplENLmnb9-BtmJKiVUW4lA2t_gPltZQlI3OsD_-gD2GKPk9ipmSOz_hseLqhdAwpRdvtclOi5gVQ8wKo3wuQFe_-bHfH__rxDOAtMCt3dpSqkqjLTJUZeb9BOggKltEldX_LCK0IoVwyWvOfq1LAcQ |
| CitedBy_id | crossref_primary_10_1016_j_ijpddr_2019_02_004 crossref_primary_10_1016_j_jpha_2020_07_005 crossref_primary_10_1021_acs_jmedchem_5b01374 crossref_primary_10_1093_jac_dky008 crossref_primary_10_1039_C9MD00042A crossref_primary_10_1128_AAC_01533_17 crossref_primary_10_1016_j_tetlet_2017_08_070 crossref_primary_10_1016_j_pt_2016_11_009 crossref_primary_10_1021_acsinfecdis_7b00212 crossref_primary_10_1021_acsinfecdis_7b00211 crossref_primary_10_1016_j_biomaterials_2019_05_032 crossref_primary_10_1038_ncomms7715 crossref_primary_10_2174_1568026623666221121154354 crossref_primary_10_1002_chem_201801090 crossref_primary_10_1371_journal_ppat_1006923 crossref_primary_10_1039_C8OB01015C crossref_primary_10_1111_brv_12565 crossref_primary_10_1042_ETLS20170097 crossref_primary_10_1038_nrd_2018_53 crossref_primary_10_1186_s12936_019_2724_z crossref_primary_10_1371_journal_pone_0178163 crossref_primary_10_1016_j_bmc_2022_116830 crossref_primary_10_1016_j_pt_2023_01_010 crossref_primary_10_1021_acsinfecdis_8b00277 crossref_primary_10_1080_22221751_2020_1870413 crossref_primary_10_1016_j_pt_2021_04_006 crossref_primary_10_1038_s41467_023_38774_1 crossref_primary_10_1093_jac_dkz443 crossref_primary_10_1016_j_slasd_2022_07_002 crossref_primary_10_1071_CH22141 crossref_primary_10_1128_AAC_01226_16 crossref_primary_10_3390_cells9102225 crossref_primary_10_1021_acs_jmedchem_2c02092 crossref_primary_10_1128_AAC_01928_15 crossref_primary_10_1021_acs_jmedchem_9b00761 crossref_primary_10_1186_s12936_016_1231_8 crossref_primary_10_1128_AAC_00379_17 crossref_primary_10_1093_femspd_ftac015 crossref_primary_10_1016_j_ebiom_2022_104065 crossref_primary_10_1016_j_ijpddr_2017_07_001 crossref_primary_10_1021_acs_jmedchem_6b00752 crossref_primary_10_1016_j_blre_2017_06_001 crossref_primary_10_1016_j_pt_2021_02_002 crossref_primary_10_1093_jac_dkw449 crossref_primary_10_1371_journal_ppat_1006180 crossref_primary_10_1021_acs_jmedchem_0c01104 crossref_primary_10_3389_fcimb_2018_00419 crossref_primary_10_1159_000484215 crossref_primary_10_1038_srep27806 crossref_primary_10_1111_bph_16144 crossref_primary_10_1128_aac_00607_22 crossref_primary_10_1111_bcp_13476 crossref_primary_10_1186_s12936_017_1730_2 crossref_primary_10_7554_eLife_29605 crossref_primary_10_1038_nm_4381 crossref_primary_10_1038_nchembio_1749 crossref_primary_10_1128_AAC_01224_16 crossref_primary_10_1126_scitranslmed_aaa6645 crossref_primary_10_1093_infdis_jiw304 crossref_primary_10_2478_acph_2023_0001 crossref_primary_10_1016_j_ejmech_2020_112955 crossref_primary_10_1242_dmm_040717 crossref_primary_10_1007_s00436_022_07673_7 crossref_primary_10_1002_ijc_30800 crossref_primary_10_1039_D1OB02331D crossref_primary_10_1021_acs_oprd_7b00046 crossref_primary_10_1016_j_ijpara_2017_05_009 crossref_primary_10_1016_j_artmed_2023_102700 crossref_primary_10_1128_spectrum_03976_22 crossref_primary_10_1016_S1473_3099_19_30611_5 crossref_primary_10_1016_j_ijpddr_2024_100536 crossref_primary_10_1007_s00018_021_03799_6 crossref_primary_10_2174_0929867331666230915093928 crossref_primary_10_4269_ajtmh_15_0007 crossref_primary_10_4155_fmc_2019_0225 crossref_primary_10_1016_j_pt_2018_07_001 crossref_primary_10_1371_journal_ppat_1005647 crossref_primary_10_3389_fchem_2018_00088 crossref_primary_10_1038_nrd4573 crossref_primary_10_1039_C5LC00945F crossref_primary_10_1007_s00044_017_1797_x crossref_primary_10_1126_science_aan4472 crossref_primary_10_1002_ardp_202100338 crossref_primary_10_1021_acs_jmedchem_5b01605 crossref_primary_10_1016_j_ejmech_2022_114324 crossref_primary_10_1016_j_bmc_2023_117339 crossref_primary_10_1038_s41586_018_0327_4 crossref_primary_10_1002_anie_201612148 crossref_primary_10_1038_s41598_021_99152_9 crossref_primary_10_1371_journal_pone_0154166 crossref_primary_10_2174_1568026623666221220140526 crossref_primary_10_1128_mbio_01178_22 crossref_primary_10_1038_s41573_023_00772_9 crossref_primary_10_1186_s12936_018_2616_7 crossref_primary_10_1186_s12936_023_04590_7 crossref_primary_10_1038_s41598_019_46500_5 crossref_primary_10_1093_infdis_jiv358 crossref_primary_10_1146_annurev_pharmtox_010715_103429 crossref_primary_10_3389_fcimb_2022_1060202 crossref_primary_10_1016_j_ejmech_2024_116599 crossref_primary_10_1038_s41598_018_26819_1 crossref_primary_10_1186_s12936_015_0957_z crossref_primary_10_1093_cid_ciab716 crossref_primary_10_1002_ange_201507264 crossref_primary_10_1016_j_drudis_2021_01_005 crossref_primary_10_1039_D1LC01058A crossref_primary_10_1074_jbc_RA118_006706 crossref_primary_10_2147_DDDT_S278588 crossref_primary_10_1039_D1RA01480C crossref_primary_10_1080_17460441_2018_1410136 crossref_primary_10_1186_s12936_016_1675_x crossref_primary_10_3390_ph15070903 crossref_primary_10_1038_nmicrobiol_2016_166 crossref_primary_10_1016_S1473_3099_20_30139_0 crossref_primary_10_1038_s41598_022_04985_7 crossref_primary_10_1021_acs_jmedchem_3c01828 crossref_primary_10_1186_s12936_024_04986_z crossref_primary_10_1016_j_actatropica_2019_04_020 crossref_primary_10_1016_j_rechem_2024_101377 crossref_primary_10_1007_s00253_018_8927_3 crossref_primary_10_1186_s12936_018_2301_x crossref_primary_10_1021_acs_jmedchem_1c00313 crossref_primary_10_1039_C7MD00637C crossref_primary_10_1128_AAC_00771_21 crossref_primary_10_1038_s41598_017_16671_0 crossref_primary_10_1016_j_ejmech_2016_01_015 crossref_primary_10_1186_s40249_016_0196_8 crossref_primary_10_1002_cjoc_201600864 crossref_primary_10_1021_acsinfecdis_3c00588 crossref_primary_10_1038_ncomms11901 crossref_primary_10_1038_s41467_017_00572_x crossref_primary_10_1186_s12936_022_04075_z crossref_primary_10_1371_journal_ppat_1009259 crossref_primary_10_1021_acscentsci_6b00086 crossref_primary_10_1038_s41598_019_54339_z crossref_primary_10_1074_jbc_RA118_003640 crossref_primary_10_1016_j_chom_2015_12_001 crossref_primary_10_1186_s12936_021_03617_1 crossref_primary_10_1021_acsinfecdis_7b00276 crossref_primary_10_1016_j_pt_2020_02_005 crossref_primary_10_1128_AAC_00087_18 crossref_primary_10_1038_s41467_022_33403_9 crossref_primary_10_3389_fphar_2022_845841 crossref_primary_10_1016_j_pt_2021_01_009 crossref_primary_10_1128_aac_01574_22 crossref_primary_10_1007_s40265_018_0911_9 crossref_primary_10_1016_j_cell_2016_07_055 crossref_primary_10_1016_j_ijpddr_2015_07_001 crossref_primary_10_1155_2020_1295381 crossref_primary_10_1186_s12936_018_2279_4 crossref_primary_10_12688_f1000research_14874_1 crossref_primary_10_1016_j_biopha_2018_05_009 crossref_primary_10_1038_ncomms15159 crossref_primary_10_1186_s12936_023_04481_x crossref_primary_10_1038_ncomms14193 crossref_primary_10_3390_molecules27010066 crossref_primary_10_1371_journal_pone_0135139 crossref_primary_10_1002_ange_201612148 crossref_primary_10_1016_j_lfs_2019_116636 crossref_primary_10_1146_annurev_micro_091014_104506 crossref_primary_10_12688_f1000research_9477_1 crossref_primary_10_1007_s10495_015_1094_4 crossref_primary_10_2174_0929867328666210803152419 crossref_primary_10_1016_j_chembiol_2024_03_002 crossref_primary_10_1007_s12272_015_0645_0 crossref_primary_10_1128_AAC_05122_14 crossref_primary_10_4269_ajtmh_20_0491 crossref_primary_10_1038_srep29241 crossref_primary_10_1016_j_ejmech_2021_113518 crossref_primary_10_1002_anie_201507264 |
| Cites_doi | 10.1186/1471-2105-10-80 10.1186/1475-2875-11-316 10.1159/000233238 10.1182/blood-2010-10-313239 10.1126/science.1193225 10.1172/JCI111913 10.1083/jcb.98.4.1201 10.1371/journal.pone.0062906 10.1016/S0021-9258(18)89189-X 10.1056/NEJMoa1315860 10.1002/ajh.23476 10.1182/blood.V46.6.965.965 10.1016/0011-2240(80)90067-X 10.1039/c2lc20857a 10.1038/nature09099 10.1128/AAC.36.4.704 10.2174/156802612799362977 10.1186/1475-2875-12-187 10.1038/ng.2648 10.1111/j.1749-6632.1989.tb22423.x 10.1016/j.chom.2012.12.006 10.3389/fphys.2014.00009 10.1371/journal.pone.0059862 10.1016/j.molbiopara.2013.04.004 10.1073/pnas.1210585109 10.1136/jcp.2006.037523 10.1128/AAC.00519-09 10.4269/ajtmh.1988.39.157 |
| ContentType | Journal Article |
| Copyright | Copyright National Academy of Sciences Dec 16, 2014 |
| Copyright_xml | – notice: Copyright National Academy of Sciences Dec 16, 2014 |
| DBID | FBQ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QG 7QL 7QP 7QR 7SN 7SS 7T5 7TK 7TM 7TO 7U9 8FD C1K FR3 H94 M7N P64 RC3 7X8 7T2 7U2 F1W H95 H97 L.G 5PM |
| DOI | 10.1073/pnas.1414221111 |
| DatabaseName | AGRIS Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic Health and Safety Science Abstracts (Full archive) Safety Science and Risk ASFA: Aquatic Sciences and Fisheries Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Aquatic Science & Fisheries Abstracts (ASFA) Professional PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Nucleic Acids Abstracts Ecology Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Entomology Abstracts Genetics Abstracts Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Chemoreception Abstracts Immunology Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts MEDLINE - Academic Aquatic Science & Fisheries Abstracts (ASFA) Professional ASFA: Aquatic Sciences and Fisheries Abstracts Health & Safety Science Abstracts Safety Science and Risk Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality |
| DatabaseTitleList | MEDLINE CrossRef Aquatic Science & Fisheries Abstracts (ASFA) Professional MEDLINE - Academic Virology and AIDS Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | (+)-SJ733, a clinical candidate for malaria |
| EISSN | 1091-6490 |
| EndPage | E5462 |
| ExternalDocumentID | 3534501021 10_1073_pnas_1414221111 25453091 111_50_E5455 US201600139217 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural Feature |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: HHSN272201100022I – fundername: NIAID NIH HHS grantid: HHSN272201100022C – fundername: NIAID NIH HHS grantid: U01 AI075517 – fundername: NIAID NIH HHS grantid: R01 AI090662 – fundername: NIAID NIH HHS grantid: AI075517 – fundername: Howard Hughes Medical Institute – fundername: PHS HHS grantid: HHSN2722011000221 – fundername: NCI NIH HHS grantid: P30 CA021765 – fundername: NIGMS NIH HHS grantid: T32 GM067547 – fundername: NIBIB NIH HHS grantid: T32 EB009383 – fundername: Howard Hughes Medical Institute (HHMI) grantid: NA – fundername: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: AI090662 – fundername: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: AI075517 |
| GroupedDBID | --- -DZ -~X .55 .GJ 0R~ 123 29P 2AX 2FS 2WC 3O- 4.4 53G 5RE 5VS 692 6TJ 79B 85S AACGO AAFWJ AANCE AAYJJ ABBHK ABOCM ABPLY ABPPZ ABPTK ABTLG ABZEH ACGOD ACIWK ACKIV ACNCT ACPRK ADULT ADZLD AENEX AEUPB AEXZC AFDAS AFFNX AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS ASUFR AS~ BKOMP CS3 D0L DCCCD DIK DNJUQ DOOOF DU5 DWIUU E3Z EBS EJD F20 F5P FBQ FRP GX1 HGD HH5 HQ3 HTVGU HYE JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KQ8 L7B LU7 MVM N9A NEJ NHB N~3 O9- OK1 P-O PNE PQQKQ R.V RHF RHI RNA RNS RPM RXW SA0 SJN TAE TN5 UKR VOH VQA W8F WH7 WHG WOQ WOW X7M XFK XSW Y6R YBH YKV YSK ZA5 ZCA ZCG ~02 ~KM - 02 0R 1AW 55 AAPBV ABFLS ADACO DZ H13 KM PQEST X XHC ABXSQ ADACV AQVQM CGR CUY CVF ECM EIF IPSME NPM AAYXX CITATION 7QG 7QL 7QP 7QR 7SN 7SS 7T5 7TK 7TM 7TO 7U9 8FD C1K FR3 H94 M7N P64 RC3 7X8 7T2 7U2 F1W H95 H97 L.G 5PM |
| ID | FETCH-LOGICAL-c503t-2bfe72ac1822e13d92ab2794c94f2f2d10b3473b1b9f3d48cdd68bcb503ac8543 |
| IEDL.DBID | RPM |
| ISSN | 0027-8424 |
| IngestDate | Tue Sep 17 21:24:12 EDT 2024 Fri Aug 16 21:11:30 EDT 2024 Fri Aug 16 23:40:38 EDT 2024 Thu Oct 10 19:38:31 EDT 2024 Fri Aug 23 03:01:25 EDT 2024 Sat Sep 28 08:06:32 EDT 2024 Wed Nov 11 00:29:54 EST 2020 Wed Dec 27 19:18:08 EST 2023 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 50 |
| Keywords | drug discovery malaria PfATP4 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c503t-2bfe72ac1822e13d92ab2794c94f2f2d10b3473b1b9f3d48cdd68bcb503ac8543 |
| Notes | http://dx.doi.org/10.1073/pnas.1414221111 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited* by Thomas E. Wellems, National Institutes of Health, Bethesda, MD, and approved October 30, 2014 (received for review July 29, 2014) Author contributions: M.B.J.-D., A.M.L., K.G.O., A.S.M.D., W.A.G., C.C.K., L.S., N.J.S., P.D.S., F.Z., V.M.A., D.A.F., F.-J.G., S.A.C., J.C.M., H.M., S.F., K.K., I.A.-B., D.E.K., J.L.D., D.M.F., and R.K.G. designed research; M.B.J.-D., D.E., Y.S., A.P., A.M.L., M.-E.M.-L., K.G.O., D.M.S., M.J.d.A., A.K.C., J.A.C., A.S.M.D., J.D., X.D., S.D., A.N.E., G.F., W.A.G., M.G.G., G.H., J.H., C.C.K., J.L., M.C.S.L., A.M., M.S.M., A.R.-A., L.S., M.S., N.J.S., P.D.S., Z.W., F.Z., and J.L.D. performed research; J.L.D. contributed new reagents/analytic tools; M.B.J.-D., D.E., Y.S., A.P., A.M.L., K.G.O., D.M.S., J.A.C., A.S.M.D., A.N.E., W.A.G., M.G.G., G.H., C.C.K., J.L., M.C.S.L., M.S.M., G.M., L.S., N.J.S., P.D.S., F.Z., D.W., S.K., A.S., V.M.A., D.A.F., F.-J.G., S.A.C., J.C.M., H.M., S.F., K.K., I.A.-B., D.E.K., J.L.D., D.M.F., and R.K.G. analyzed data; and D.A.F., K.K., D.E.K., J.L.D., and R.K.G. wrote the paper. |
| OpenAccessLink | https://www.pnas.org/content/pnas/111/50/E5455.full.pdf |
| PMID | 25453091 |
| PQID | 1639503236 |
| PQPubID | 42026 |
| PageCount | 1 |
| ParticipantIDs | proquest_miscellaneous_1660399816 proquest_miscellaneous_1637995204 crossref_primary_10_1073_pnas_1414221111 pubmed_primary_25453091 pnas_primary_111_50_E5455 proquest_journals_1639503236 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4273362 fao_agris_US201600139217 |
| ProviderPackageCode | RNA PNE |
| PublicationCentury | 2000 |
| PublicationDate | 2014-12-16 |
| PublicationDateYYYYMMDD | 2014-12-16 |
| PublicationDate_xml | – month: 12 year: 2014 text: 2014-12-16 day: 16 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Washington |
| PublicationSeriesTitle | PNAS Plus |
| PublicationTitle | Proceedings of the National Academy of Sciences - PNAS |
| PublicationTitleAlternate | Proc Natl Acad Sci U S A |
| PublicationYear | 2014 |
| Publisher | National Academy of Sciences National Acad Sciences |
| Publisher_xml | – name: National Academy of Sciences – name: National Acad Sciences |
| References | 16775118 - J Clin Pathol. 2007 May;60(5):549-54 22826220 - Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):13052-7 24523696 - Front Physiol. 2014 Jan 30;5:9 23674388 - Am J Hematol. 2013 Aug;88(8):682-9 20485428 - Nature. 2010 May 20;465(7296):311-5 22958514 - Malar J. 2012;11:316 22242845 - Curr Top Med Chem. 2012;12(5):473-83 21427291 - Blood. 2011 May 12;117(19):5215-23 1203539 - Blood. 1975 Dec;46(6):965-76 1503432 - Antimicrob Agents Chemother. 1992 Apr;36(4):704-11 19710527 - Cell Physiol Biochem. 2009;24(3-4):133-40 7471785 - Cryobiology. 1980 Dec;17(6):530-9 19596869 - Antimicrob Agents Chemother. 2009 Oct;53(10):4533-6 3988747 - J Biol Chem. 1985 Apr 25;260(8):5131-8 23555811 - PLoS One. 2013;8(3):e59862 23414762 - Cell Host Microbe. 2013 Feb 13;13(2):227-37 4008648 - J Clin Invest. 1985 Jun;75(6):1965-72 19267900 - BMC Bioinformatics. 2009;10:80 3044154 - Am J Trop Med Hyg. 1988 Aug;39(2):157-65 24399969 - Front Physiol. 2013 Dec 25;4:387 23742293 - Malar J. 2013;12:187 20813948 - Science. 2010 Sep 3;329(5996):1175-80 22318405 - Lab Chip. 2012 Mar 21;12(6):1143-50 23623918 - Mol Biochem Parasitol. 2013 May;189(1-2):1-4 2660673 - Ann N Y Acad Sci. 1989;554:217-24 23715326 - Nat Genet. 2013 Jun;45(6):589-90 23798988 - PLoS One. 2013;8(6):e62906 26430239 - Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5764 6546931 - J Cell Biol. 1984 Apr;98(4):1201-8 25075833 - N Engl J Med. 2014 Jul 31;371(5):403-10 Evans E (e_1_3_4_27_2) 1984; 98 Burrows JN (e_1_3_4_4_2) 2013; 12 World Health Organization (e_1_3_4_1_2) 2012 Jiménez-Díaz MB (e_1_3_4_9_2) 2009; 53 Rathod PK (e_1_3_4_14_2) 1992; 36 Kwan JM (e_1_3_4_17_2) 2013; 88 de Back DZ (e_1_3_4_19_2) 2014; 5 Lutz HU (e_1_3_4_15_2) 2013; 4 Chatterjee AK (e_1_3_4_5_2) 2012; 12 Guo Q (e_1_3_4_26_2) 2012; 12 Rottmann M (e_1_3_4_8_2) 2010; 329 Williams RJ (e_1_3_4_28_2) 1980; 17 Xie C (e_1_3_4_11_2) 2009; 10 Schwartz RS (e_1_3_4_20_2) 1985; 75 Klausner MA (e_1_3_4_22_2) 1975; 46 Anthony MP (e_1_3_4_2_2) 2012; 11 Neafsey DE (e_1_3_4_6_2) 2013; 45 Spillman NJ (e_1_3_4_13_2) 2013; 189 Lee P (e_1_3_4_29_2) 1988; 39 Mohandas N (e_1_3_4_18_2) 1989; 554 Lee SJ (e_1_3_4_16_2) 2011; 117 Spangenberg T (e_1_3_4_3_2) 2013; 8 Föller M (e_1_3_4_23_2) 2009; 24 Spillman NJ (e_1_3_4_12_2) 2013; 13 Guiguemde WA (e_1_3_4_7_2) 2010; 465 Schroit AJ (e_1_3_4_21_2) 1985; 260 White NJ (e_1_3_4_30_2) 2014; 371 Ahlgrim C (e_1_3_4_25_2) 2013; 8 Piagnerelli M (e_1_3_4_24_2) 2007; 60 Park DJ (e_1_3_4_10_2) 2012; 109 |
| References_xml | – volume: 10 start-page: 80 year: 2009 ident: e_1_3_4_11_2 article-title: CNV-seq, a new method to detect copy number variation using high-throughput sequencing publication-title: BMC Bioinformatics doi: 10.1186/1471-2105-10-80 contributor: fullname: Xie C – volume: 11 start-page: 316 year: 2012 ident: e_1_3_4_2_2 article-title: The global pipeline of new medicines for the control and elimination of malaria publication-title: Malar J doi: 10.1186/1475-2875-11-316 contributor: fullname: Anthony MP – volume: 4 start-page: 387 year: 2013 ident: e_1_3_4_15_2 article-title: Mechanisms tagging senescent red blood cells for clearance in healthy humans publication-title: Front Physiol contributor: fullname: Lutz HU – volume: 24 start-page: 133 year: 2009 ident: e_1_3_4_23_2 article-title: Suicide for survival—death of infected erythrocytes as a host mechanism to survive malaria publication-title: Cell Physiol Biochem doi: 10.1159/000233238 contributor: fullname: Föller M – volume: 117 start-page: 5215 year: 2011 ident: e_1_3_4_16_2 article-title: Mechanism for phosphatidylserine-dependent erythrophagocytosis in mouse liver publication-title: Blood doi: 10.1182/blood-2010-10-313239 contributor: fullname: Lee SJ – volume: 329 start-page: 1175 year: 2010 ident: e_1_3_4_8_2 article-title: Spiroindolones, a potent compound class for the treatment of malaria publication-title: Science doi: 10.1126/science.1193225 contributor: fullname: Rottmann M – volume: 75 start-page: 1965 year: 1985 ident: e_1_3_4_20_2 article-title: Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes publication-title: J Clin Invest doi: 10.1172/JCI111913 contributor: fullname: Schwartz RS – volume: 98 start-page: 1201 year: 1984 ident: e_1_3_4_27_2 article-title: Adhesivity and rigidity of erythrocyte membrane in relation to wheat germ agglutinin binding publication-title: J Cell Biol doi: 10.1083/jcb.98.4.1201 contributor: fullname: Evans E – volume: 8 start-page: e62906 year: 2013 ident: e_1_3_4_3_2 article-title: The open access malaria box: A drug discovery catalyst for neglected diseases publication-title: PLoS ONE doi: 10.1371/journal.pone.0062906 contributor: fullname: Spangenberg T – volume: 260 start-page: 5131 year: 1985 ident: e_1_3_4_21_2 article-title: In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)89189-X contributor: fullname: Schroit AJ – volume: 371 start-page: 403 year: 2014 ident: e_1_3_4_30_2 article-title: Spiroindolone KAE609 for falciparum and vivax malaria publication-title: N Engl J Med doi: 10.1056/NEJMoa1315860 contributor: fullname: White NJ – volume: 88 start-page: 682 year: 2013 ident: e_1_3_4_17_2 article-title: Microfluidic analysis of cellular deformability of normal and oxidatively damaged red blood cells publication-title: Am J Hematol doi: 10.1002/ajh.23476 contributor: fullname: Kwan JM – volume: 46 start-page: 965 year: 1975 ident: e_1_3_4_22_2 article-title: Contrasting splenic mechanisms in the blood clearance of red blood cells and colloidal particles publication-title: Blood doi: 10.1182/blood.V46.6.965.965 contributor: fullname: Klausner MA – volume: 17 start-page: 530 year: 1980 ident: e_1_3_4_28_2 article-title: The relationship between cell injury and osmotic volume reduction: II. Red cell lysis correlates with cell volume rather than intracellular salt concentration publication-title: Cryobiology doi: 10.1016/0011-2240(80)90067-X contributor: fullname: Williams RJ – volume: 12 start-page: 1143 year: 2012 ident: e_1_3_4_26_2 article-title: Microfluidic biomechanical assay for red blood cells parasitized by Plasmodium falciparum publication-title: Lab Chip doi: 10.1039/c2lc20857a contributor: fullname: Guo Q – volume: 465 start-page: 311 year: 2010 ident: e_1_3_4_7_2 article-title: Chemical genetics of Plasmodium falciparum publication-title: Nature doi: 10.1038/nature09099 contributor: fullname: Guiguemde WA – volume: 36 start-page: 704 year: 1992 ident: e_1_3_4_14_2 article-title: Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.36.4.704 contributor: fullname: Rathod PK – volume: 12 start-page: 473 year: 2012 ident: e_1_3_4_5_2 article-title: Back to the future: Lessons learned in modern target-based and whole-cell lead optimization of antimalarials publication-title: Curr Top Med Chem doi: 10.2174/156802612799362977 contributor: fullname: Chatterjee AK – volume: 12 start-page: 187 year: 2013 ident: e_1_3_4_4_2 article-title: Designing the next generation of medicines for malaria control and eradication publication-title: Malar J doi: 10.1186/1475-2875-12-187 contributor: fullname: Burrows JN – volume: 45 start-page: 589 year: 2013 ident: e_1_3_4_6_2 article-title: Genome sequencing sheds light on emerging drug resistance in malaria parasites publication-title: Nat Genet doi: 10.1038/ng.2648 contributor: fullname: Neafsey DE – volume: 554 start-page: 217 year: 1989 ident: e_1_3_4_18_2 article-title: Cell membrane and volume changes during red cell development and aging publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.1989.tb22423.x contributor: fullname: Mohandas N – volume: 13 start-page: 227 year: 2013 ident: e_1_3_4_12_2 article-title: Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials publication-title: Cell Host Microbe doi: 10.1016/j.chom.2012.12.006 contributor: fullname: Spillman NJ – volume: 5 start-page: 9 year: 2014 ident: e_1_3_4_19_2 article-title: Of macrophages and red blood cells: A complex love story publication-title: Front Physiol doi: 10.3389/fphys.2014.00009 contributor: fullname: de Back DZ – volume: 8 start-page: e59862 year: 2013 ident: e_1_3_4_25_2 article-title: Flow cytometric assessment of erythrocyte shape through analysis of FSC histograms: Use of kurtosis and implications for longitudinal evaluation publication-title: PLoS ONE doi: 10.1371/journal.pone.0059862 contributor: fullname: Ahlgrim C – volume: 189 start-page: 1 year: 2013 ident: e_1_3_4_13_2 article-title: Na+ extrusion imposes an acid load on the intraerythrocytic malaria parasite publication-title: Mol Biochem Parasitol doi: 10.1016/j.molbiopara.2013.04.004 contributor: fullname: Spillman NJ – volume: 109 start-page: 13052 year: 2012 ident: e_1_3_4_10_2 article-title: Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1210585109 contributor: fullname: Park DJ – volume: 60 start-page: 549 year: 2007 ident: e_1_3_4_24_2 article-title: Assessment of erythrocyte shape by flow cytometry techniques publication-title: J Clin Pathol doi: 10.1136/jcp.2006.037523 contributor: fullname: Piagnerelli M – volume-title: World Malaria Report year: 2012 ident: e_1_3_4_1_2 contributor: fullname: World Health Organization – volume: 53 start-page: 4533 year: 2009 ident: e_1_3_4_9_2 article-title: Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00519-09 contributor: fullname: Jiménez-Díaz MB – volume: 39 start-page: 157 year: 1988 ident: e_1_3_4_29_2 article-title: X-ray microanalysis of Plasmodium falciparum and infected red blood cells: Effects of qinghaosu and chloroquine on potassium, sodium, and phosphorus composition publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.1988.39.157 contributor: fullname: Lee P |
| SSID | ssj0009580 |
| Score | 2.5949748 |
| Snippet | Drug discovery for malaria has been transformed in the last 5 years by the discovery of many new lead compounds identified by phenotypic screening. The process... Significance Useful antimalarial drugs must be rapidly acting, highly efficacious, and have low potential for developing resistance. (+)-SJ733 targets a... Useful antimalarial drugs must be rapidly acting, highly efficacious, and have low potential for developing resistance. (+)-SJ733 targets a Plasmodium... |
| SourceID | pubmedcentral proquest crossref pubmed pnas fao |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | E5455 |
| SubjectTerms | Adenosine triphosphatase Antimalarials - pharmacokinetics Antimalarials - pharmacology Biological Sciences Calcium-Transporting ATPases - genetics Calcium-Transporting ATPases - metabolism Cellular Senescence - drug effects Drug Discovery Drug Resistance - genetics Erythrocytes Erythrocytes - drug effects Flow Cytometry Heterocyclic Compounds, 4 or More Rings - pharmacokinetics Heterocyclic Compounds, 4 or More Rings - pharmacology High-Throughput Screening Assays Homeostasis Isoquinolines - pharmacokinetics Isoquinolines - pharmacology Malaria Malaria - drug therapy Models, Molecular Molecular Structure Mutation Parasitic protozoa Plasmodium - drug effects Plasmodium falciparum PNAS Plus |
| Title | (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium |
| URI | http://www.pnas.org/content/111/50/E5455.abstract https://www.ncbi.nlm.nih.gov/pubmed/25453091 https://www.proquest.com/docview/1639503236 https://search.proquest.com/docview/1637995204 https://search.proquest.com/docview/1660399816 https://pubmed.ncbi.nlm.nih.gov/PMC4273362 |
| Volume | 111 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BatwwEB2yOfVSmqRt3CZBhR42tM7akizbxxASQiBlIVnIzUiy1Rhqe8l6oZ-fGa_tdEvpITeDRoOsmZHe2JongK86Jhwtcx9348KXOoh8k5rct1qpQkhpQ0ffO25_qOuFvHmIHnYgGmphukP71pRn9a_qrC4fu7OVy8rOhnNis_ntheRE4sdnE5jgw5Cij0y7yabuhOPyK7kc-HxiMVvWeoVLA332oJWCiIARQIggDbd2pYnTDXGdovS_cOffxyf_2I-u3sHbHkiy882A92CnqPdhrw_VFZv2fNKnB_B7-u3Uv7vBd_jONBtKIZmlghbK9xniVlZpTHFLzdpH3TJt2xXrb_Bh5_dzydqGYfKObsCe9LLMGdWG-F3VCSJW1InxQu7DGsfmiMerJi_X1XtYXF3eX1z7_YULvo0C0frcuCLm2mLOwYtQ5CnXhmPA2lQ67ngeBkbIWJjQpE7kMrF5rhJjDXbWNomk-AC7dVMXh8BkrFWROK0CJ9DgCDwM1ypUjm4gQ00eTIcJz5YbXo2s-x8ei4wmPnsxkweHaJBM_8RVL1vcceLEI-CKyZQHXic8asBsJgqyS7Rq5MHRYLqsj0vUioAMR8uF8uDL2IwRRb9JdF00606GWPJ4IP8nowKEdkmIej5uvGEcxOBTHsRbfjIKEKP3dgs6esfs3Tv2p1f3_AxvcH46JspQHcFu-7QujhE1teaE9qzopIuVZ4LdEsE |
| link.rule.ids | 230,315,733,786,790,891,27957,27958,53827,53829 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9t4wFegPGxBQYYiYdOkDaxHSd5nKZNZaxTpbVob5E_EhZtSao1lRB_Pec0CXRCSPDs8ymJ786_c-5-BvggQ4ujuXFxN05dLr3AVbEyrpZCpIxz7Wf2vGNyIcZzfnYVXG1B0PXCNEX7WuXD8rYYlvl1U1u5KPSoqxMbTSfHnFoSPzrahgforzTskvSeazdad55QDMCc8o7RJ2SjRSmXGBzswYeNFZYKGCEE82J_Y1_azmRl2U5R-k_I834B5W870ukT-Nq9y7oQ5Wa4qtVQ_7hH8_jPL_sUHrcYlRyth3dhKy2fwW4bBZZk0FJVHz6H74OPh-7lGU79RCTpuiyJtr0y9iiBICQmhcTsOZekvpY1kbpekvZyIHI0m3JSVyQvDVoYuZOL3BDbduI2DS0IhlEnuqK1TFJlZIpQv6hMvipewPz0ZHY8dtu7HFwdeKx2qcrSkEqN6QxNfWZiKhXFWKBjntGMGt9TjIdM-SrOmOGRNkZESiucLHUUcPYSdsqqTPeB8FCKNMqk8DKGtoSYRlEpfJHZy81QkwODbiWTxZqyI2l-tYcssSua_Fp_B_ZxpRP5DQNqMr-klm7PYmLM0xxwGuFeAyZKgZecoLkEDhx0NpG0Lo9aEevh01ImHHjfD6Oz2j8wskyrVSNjCfiox_8mIzxEjZGPevbWZtY_RGesDoQbBtgLWLLwzRE0q4Y0vDWjV_898x08HM8m58n554svr-ERfquG8NIXB7BT363SNwjOavW2ccWfCB8zzg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZokRAXSnm0KQWMxGEryCaxHSc5VqWrUmi1UrtSxSXyI6YR5KFuVkL8esZ50a0Qh54zHiXx5_E39vgzQu9FZHk00y7MxpnLhB-6MpHaVYLzjDKmAmPXO87O-cmCnV6FV7eu-mqL9pXMp-XPYlrm121tZV0ob6gT8-ZnR4xYET_i1dp4G-ghjFmSDIn6qLcbd6dPCARhRtig6hNRry7FEgKEXfyw8cLKAQONoH4SrM1NG0ZUVvEUrP_FPu8WUd6alWZb6NvwPV0xyo_pqpFT9fuO1OO9PvgpetJzVXzYmWyjB1n5DG330WCJJ71k9cFz9Gvy4cC9OIXmH7HAw2lLrOyZGbukgIEa40JAFp0L3FyLBgvVLHF_SRA-vJwz3FQ4LzUgDd-IOtfYHj9x24MtQIrBJwxJi1BcGTwHyl9UOl8VL9Bidnx5dOL2dzq4KvRp4xJpsogIBWkNyQKqEyIkgZigEmaIITrwJWURlYFMDNUsVlrzWCoJjYWKQ0Zfos2yKrNdhFkkeBYbwX1DAVPAbSQRPODGXnIGnhw0GXozrTvpjrTdco9oans1_YsBB-1Cb6fiOwTWdHFBrOye5caQrznIaY1HD5AwhX56DJAJHbQ_4CLthz54Bc4Hb0sod9C78TEMWrsTI8qsWrU2VoiP-Ox_NtwH9hgH4Geng9r4EgNgHRStgXA0sKLh608AWq14eA-lvXu3fIsezT_N0q-fz7-8Qo_hV7W6lwHfR5vNzSp7DRytkW_a0fgHxoM2Tg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%28%2B%29-SJ733%2C+a+clinical+candidate+for+malaria+that+acts+through+ATP4+to+induce+rapid+host-mediated+clearance+of+Plasmodium&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Jimenez-Diaz%2C+Maria+Belen&rft.au=Ebert%2C+Daniel&rft.au=Salinas%2C+Yandira&rft.au=Pradhan%2C+Anupam&rft.date=2014-12-16&rft.issn=0027-8424&rft.volume=111&rft.issue=50&rft.spage=5455&rft.epage=5455&rft_id=info:doi/10.1073%2Fpnas.1414221111&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F111%2F50.cover.gif |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F111%2F50.cover.gif |